The role and clinical value of inflammation factors in non-small cell lung cancer

doi:10.19983/j.issn.2096-8493.20260089

Abstract

Abstract:

Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancer cases and ranks as the leading cause of cancer-related death worldwide. In the tumor microenvironment, dysregulated expression of inflammatory cytokines serves as a core driver of immunosuppression and therapeutic resistance, and such dysregulated cytokine networks further facilitate tumor initiation and progression. Based on the latest research advances on inflammatory cytokines and tumor progression, this review systematically summarizes the biological functions and regulatory mechanisms of nine key cytokines involved in NSCLC. Classified by their functional characteristics and biological roles, this review further elaborates the action mechanisms of interleukin-1β, interleukin-6, interleukin-8, interleukin-10, interleukin-12p70, interleukin-17, tumor necrosis factor-α, interferon-α and interferon-γ. In-depth analysis of the context-dependent regulatory patterns of these cytokines not only facilitates the identification of candidate biomarkers for predicting response and adverse events to immune checkpoint inhibitors, but also lays a theoretical foundation for the development of novel combination strategies targeting specific signaling axes.

Key words: Carcinoma, non-small-cell lung, Chemokines, Cytokines, Interleukins

CLC Number:

R734

Li Jingjing, Lu Nihong, Yang Yan. The role and clinical value of inflammation factors in non-small cell lung cancer[J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 700-707. doi: 10.19983/j.issn.2096-8493.20260089

References 68

[1]	郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231. doi:10.3760/cma.j.cn112152-20240119-00035.
[2]	Wu X, Wu J, Dai T, et al. β-elemene promotes miR-127-3p maturation, induces NSCLCs autophagy, and enhances macrophage M1 polarization through exosomal communication[J]. J Pharm Anal, 2024, 14(9):100961. doi:10.1016/j.jpha.2024.03.002.
[3]	Abolfathi H, Sheikhpour M, Shahraeini S S, et al. Studies in lung cancer cytokine proteomics: a review[J]. Expert Rev Proteomics, 2021, 18(1):49-64. doi:10.1080/14789450.2021.1892491.
[4]	Lv T, Fan R, Wu J, et al. Tumor-associated macrophages: key players in the non-small cell lung cancer tumor microenvironment[J]. Cancer Med, 2025, 14(3):e70670. doi:10.1002/cam4.70670.
[5]	Zhao Y, Jia S, Zhang K, et al. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer[J]. Front Oncol, 2023, 13:1064616. doi:10.3389/fonc.2023.1064616.
[6]	Rydberg Millrud C, Deronic A, Grönberg C, et al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy[J]. Cancer Immunol Immunother, 2023, 72(3):667-678. doi:10.1007/s00262-022-03277-3.
[7]	Liu D, Liu X Q, Kiefl R, et al. Effects of the NF-κB pathway agonist IL-1β on non-small cell lung cancer cell lines[J]. Ann Clin Lab Sci, 2021, 51(3):295-301. pmid: 34162558
[8]	Hirayama A, Tanaka K, Tsutsumi H, et al. Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β[J]. Front Immunol, 2023, 14:1192861. doi:10.3389/fimmu.2023.1192861.
[9]	Ghiringhelli F, Rébé C. The promise of IL-1β modulation in NSCLC clinical context[J]. Front Immunol, 2026, 17:1773253. doi:10.3389/fimmu.2026.1773253.
[10]	Kaur S, Bansal Y, Kumar R, et al. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors[J]. Bioorg Med Chem, 2020, 28(5):115327. doi:10.1016/j.bmc.2020.115327.
[11]	Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers[J]. Front Oncol, 2022, 12:1023177. doi:10.3389/fonc.2022.1023177.
[12]	Yao Y, Tao G, Xie D, et al. Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer[J]. Crit Rev Oncol Hematol, 2025, 214:104861. doi:10.1016/j.critrevonc.2025.104861.
[13]	Hu Z, Sui Q, Jin X, et al. IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma[J]. J Exp Clin Cancer Res, 2024, 43(1):63. doi:10.1186/s13046-024-02989-x. pmid: 38424624
[14]	陈平, 张鹤, 赵云龙. 细胞因子与非小细胞肺癌手术患者预后关系的研究进展[J]. 医学综述, 2022, 28 (14): 2795-2800. doi:10.3969/j.issn.1006-2084.2022.14.016.
[15]	郭莹, 高天慧, 赵孟阳, 等. 晚期非小细胞肺癌淋巴细胞亚群及细胞因子与免疫疗效的关系研究[J]. 中华全科医学, 2022, 20(9):1462-1465. doi:10.16766/j.cnki.issn.1674-4152.002623.
[16]	Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)[J]. Thorac Cancer, 2020, 11(4):835-839. doi:10.1111/1759-7714.13341. pmid: 32043828
[17]	Cheng Q, Zuo X, Wang Z, et al. Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion[J]. Respir Res, 2025, 26(1):180. doi:10.1186/s12931-025-03263-0.
[18]	Favaro F, Luciano-Mateo F, Moreno-Caceres J, et al. TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma[J]. Cell Death Dis, 2022, 13(12):1046. doi:10.1038/s41419-022-05495-0. pmid: 36522309
[19]	Lin Z, Liao L, Zhao S, et al. Corylin inhibits the progression of non-small cell lung cancer cells by regulating NF-κB signaling pathway via targeting p65[J]. Phytomedicine, 2023, 110:154627. doi:10.1016/j.phymed.2022.154627.
[20]	王溪溪, 王沁尧, 尹乙杰, 等. CXCL8在肿瘤耐药中的作用[J]. 生命的化学, 2023, 43(11):1758-1766. doi:10.13488/j.smhx.20230512.
[21]	Ramachandra N, Gupta M, Schwartz L, et al. Role of IL8 in myeloid malignancies[J]. Leuk Lymphoma, 2023, 64(11):1742-1751. doi:10.1080/10428194.2023.2232492.
[22]	Kang P, Liu D, Li L, et al. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade[J]. Cytokine, 2023, 163:156133. doi:10.1016/j.cyto.2023.156133.
[23]	Zou D, Song A, Yong W. Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis[J]. Front Oncol, 2023, 13:1176574. doi:10.3389/fonc.2023.1176574.
[24]	Wang X, Huang H, Zhang L, et al. Elevated levels of neutrophil related chemokine citrullinated histone H3, interleukin-8 and C-reaction protein in patients with immune checkpoint inhibitor therapy: predictive biomarkers for response to treatment[J]. Cancer Cell Int, 2023, 23(1):167. doi:10.1186/s12935-023-02994-8. pmid: 37580733
[25]	Wang Z, Chen Y, Wu H, et al. Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses[J]. Sci Rep, 2024, 14(1):7366. doi:10.1038/s41598-024-57997-w. pmid: 38548896
[26]	Tait Wojno E D, Hunter C A, Stumhofer J S. The immunobio-logy of the interleukin-12 family: room for discovery[J]. Immunity, 2019, 50(4):851-870. doi:10.1016/j.immuni.2019.03.011. pmid: 30995503
[27]	Park H, Kang I, Lee S, et al. Local delivery of IL-12 mRNA and indoximod prodrug potentiates antitumor immunity by increasing T cell effector function[J]. J Control Release, 2025, 385:113970. doi:10.1016/j.jconrel.2025.113970.
[28]	Horton B L, D’Souza A D, Zagorulya M, et al. Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2[J]. JCI Insight, 2023, 8(19):e172728. doi:10.1172/jci.insight.172728.
[29]	段玉玲, 张阳, 白林林, 等. 白细胞介素-12通过抑制 STAT3 途径调控非小细胞肺癌细胞生物学行为及免疫逃逸因子分泌的研究[J]. 免疫学杂志, 2023, 39(5):403-408. doi:10.13431/j.cnki.immunol.j.20230052.
[30]	Facheris G, Bruni A, Nardone V, et al. Role of cytokines in oligometastatic non-small-cell lung cancer treated with stereotactic radiation therapy: an observational pilot study[J]. Biomolecules, 2026, 16(3):423. doi:10.3390/biom16030423.
[31]	Rosewell Shaw A, Morita D, Porter C E, et al. IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer[J]. Mol Ther Oncol, 2024, 32(4):200899. doi:10.1016/j.omton.2024.200899.
[32]	Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10[J]. J Exp Med, 2020, 217(1):e20190418. doi:10.1084/jem.20190418.
[33]	Du W, Ouyang Y, Feng X, et al. IL-10RA promotes lung cancer cell proliferation by increasing fatty acid oxidation via STAT3 signaling pathway[J]. Pulm Pharmacol Ther, 2025, 88:102344. doi:10.1016/j.pupt.2025.102344.
[34]	Zhang S, Sun L, Zuo J, et al. Tumor associated neutrophils governs tumor progression through an IL-10/STAT3/PD-L1 feedback signaling loop in lung cancer[J]. Transl Oncol, 2024, 40:101866. doi:10.1016/j.tranon.2023.101866.
[35]	Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: its implications in cancer immunotherapy[J]. SAGE Open Med, 2022, 10:20503121211069012. doi:10.1177/20503121211069012.
[36]	Wang Y, Jia J, Wang F, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication[J]. Signal Transduct Target Ther, 2024, 9(1):236. doi:10.1038/s41392-024-01937-7.
[37]	El-Shemi A G, Alqurashi A, Abdulrahman J A, et al. IL-10-directed cancer immunotherapy: preclinical advances, clinical insights, and future perspectives[J]. Cancers (Basel), 2025, 17(6):1012. doi:10.3390/cancers17061012.
[38]	Wang H, Zhou F, Zhao C, et al. Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy[J]. Front Immunol, 2022, 13:840313. doi:10.3389/fimmu.2022.840313.
[39]	Zhang X, Li B, Lan T, et al. The role of interleukin-17 in inflammation-related cancers[J]. Front Immunol, 2025, 15:1479505. doi:10.3389/fimmu.2024.1479505.
[40]	Huangfu L, Li R, Huang Y, et al. The IL-17 family in diseases: from bench to bedside[J]. Signal Transduct Target Ther, 2023, 8(1):402. doi:10.1038/s41392-023-01620-3.
[41]	Wang R, Yang L, Zhang C, et al. Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer[J]. Oncoimmunology, 2018, 7(11):e1461303. doi:10.1080/2162402X.2018.1461303.
[42]	Ge W, Gong Y, Li Y, et al. IL-17 induces non-small cell lung cancer metastasis via GCN5-dependent SOX4 acetylation enhancing MMP9 gene transcription and expression[J]. Mol Carcinog, 2023, 62(9):1399-1416. doi:10.1002/mc.23585.
[43]	何程远, 杨红宇, 谭钰晶, 等. IL-17A在非小细胞肺癌组织中的表达及其通过NF-κB信号通路对VEGF表达的调控作用[J]. 吉林大学学报(医学版), 2022, 48(4):1003-1009. doi:10.13481/j.1671-587X.20220421.
[44]	Liao H, Chang X, Gao L, et al. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer[J]. J Transl Med, 2023, 21(1):828. doi:10.1186/s12967-023-04365-3. pmid: 37978543
[45]	Dutkowska A, Szmyd B, Kaszkowiak M, et al. Expression of inflammatory interleukins and selected miRNAs in non-small cell lung cancer[J]. Sci Rep, 2021, 11(1):5092. doi:10.1038/s41598-021-84408-1. pmid: 33658555
[46]	Benoot T, Piccioni E, De Ridder K, et al. TNFα and immune checkpoint inhibition: friend or foe for lung cancer?[J]. Int J Mol Sci, 2021, 22(16):8691. doi:10.3390/ijms22168691.
[47]	Gong K, Guo G, Beckley N, et al. Tumor necrosis factor in lung cancer: complex roles in biology and resistance to treatment[J]. Neoplasia, 2021, 23(2):189-196. doi:10.1016/j.neo.2020.12.006. pmid: 33373873
[48]	Yu K, Yu C, Jiao L, et al. The function and therapeutic implications of TNF signaling in MDSCs[J]. Biomolecules, 2022, 12(11):1627. doi:10.3390/biom12111627.
[49]	Mahdavi Sharif P, Jabbari P, Razi S, et al. Importance of TNF-alpha and its alterations in the development of cancers[J]. Cytokine, 2020, 130:155066. doi:10.1016/j.cytokine.2020.155066.
[50]	苏舒, 吕昕, 祁亮, 等. 外周血免疫指标在肺癌患者免疫治疗中的预测价值[J]. 中国肺癌杂志, 2023, 26(12):901-909. doi:10.3779/j.issn.1009-3419.2023.102.38.
[51]	Zhu Y X, Li Z Y, Yu Z L, et al. The underlying mechanism and therapeutic potential of IFNs in viral-associated cancers[J]. Life Sci, 2025, 361:123301. doi:10.1016/j.lfs.2024.123301.
[52]	Meng X, Chen Y, Macip S, et al. PML-II regulates ERK and AKT signal activation and IFNα-induced cell death[J]. Cell Commun Signal, 2021, 19:70. doi:10.1186/s12964-021-00756-5. pmid: 34215258
[53]	Fan L, Xu G, Cao J, et al. Type I interferon promotes antitumor T cell response in CRPC by regulating MDSC[J]. Cancers (Basel), 2021, 13(21):5574. doi:10.3390/cancers13215574.
[54]	Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy[J]. Cell Mol Life Sci, 2022, 79(3):191. doi:10.1007/s00018-022-04219-z. pmid: 35292881
[55]	Brown S R, Vomhof-DeKrey E E, Al-Marsoummi S, et al. Schlafen family intra-regulation by IFN-α2 in triple-negative breast cancer[J]. Cancers (Basel), 2023, 15(23):5658. doi:10.3390/cancers15235658.
[56]	Hu J, Pan M, Wang Y, et al. Functional plasticity of neutrophils after low- or high-dose irradiation in cancer treatment-a mini review[J]. Front Immunol, 2023, 14:1169670. doi:10.3389/fimmu.2023.1169670.
[57]	Chen X, Wang K. Mesenchymal stem cells carrying IFN-α and IFN-β overexpression genes inhibit non-small cell lung cancer via the JAK/STAT pathway[J]. J Evol Biochem Phys, 2023, 59(4):1136-1149. doi:10.1134/S0022093023040105.
[58]	Hou T, Jiang S, Wang Y, et al. Alpha thalassemia/intellectual disability X-linked deficiency sensitizes non-small cell lung cancer to immune checkpoint inhibitors[J]. Front Oncol, 2020, 10:608300. doi:10.3389/fonc.2020.608300.
[59]	Zhu Y, Chen M, Xu D, et al. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma[J]. Cell Mol Immunol, 2022, 19(6):726-737. doi:10.1038/s41423-022-00848-3. pmid: 35459855
[60]	Ding H, Wang G, Yu Z, et al. Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway[J]. Biomed Pharmacother, 2022, 155:113683. doi:10.1016/j.biopha.2022.113683.
[61]	Di Nitto C, Gilardoni E, Mock J, et al. An engineered IFNγ-antibody fusion protein with improved tumor-homing properties[J]. Pharmaceutics, 2023, 15(2):377. doi:10.3390/pharmaceutics15020377.
[62]	Jing Z L, Liu G L, Zhou N, et al. Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells[J]. Sci Rep, 2024, 14(1):6053. doi:10.1038/s41598-024-56681-3.
[63]	Jorgovanovic D, Song M, Wang L, et al. Roles of IFN-γ in tumor progression and regression: a review[J]. Biomark Res, 2020, 8:49. doi:10.1186/s40364-020-00228-x. pmid: 33005420
[64]	Zhao N, Yi Y, Cao W, et al. Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy[J]. Front Oncol, 2022, 12:923531. doi:10.3389/fonc.2022.923531.
[65]	梁振宇, 万启明, 彭炜惟, 等. 外周血细胞因子对非小细胞肺癌的预后及免疫治疗的疗效的预测作用[J]. 中国肿瘤外科杂志, 2023, 15(2):116-122. doi:10.3969/j.issn.1674-4136.2023.02.003.
[66]	Ridker P M, MacFadyen J G, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, 390(10105):1833-1842. doi:10.1016/S0140-6736(17)32247-X. pmid: 28855077
[67]	Lu X, Tan X, Kim E J, et al. Cell-cell interactions as predictive and prognostic markers for drug responses in cancer[J]. Genome Med, 2025, 17(1):117. doi:10.1186/s13073-025-01518-5. pmid: 41063141
[68]	Konen J M, Wu H, Gibbons D L. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities[J]. Trends Pharmacol Sci, 2024, 45(6):520-536. doi:10.1016/j.tips.2024.04.006. pmid: 38744552